ScreeningNCT07337083
Prediabetes in End Stage Renal Disease on Dialysis
An observational study of Screening and Pre Diabetic, run by Sohag University at 2 sites in Egypt.
Trial summary
Prediabetes is a highly prevalent condition, affecting about one-third of adults in the United States Patients with prediabetes have an increased risk for diabetes, with 2% to 10% progressing to diabetes each yea Although prediabetes is frequently considered an intermediary stage in the progression between… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Screening, Pre Diabetic, Chronic Renal Failure (CRF)
- How many people
- 262 participants
- Where
- 2 sitesEgypt
- Study dates
- 13 Apr 2025to 12 Oct 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population is defined as adult patients (aged 18 years or older) with End-Stage Renal Disease (ESRD) who are currently on dialysis. This population will be recruited from a single center: Sohag Faculty of Medicine, Sohag University, Egypt.
Who may be able to join
- End stage renal disease on dialysis patients aged ≥ 18 years old.
Who cannot join
- Patients previously diagnosed with prediabetes.
- Patients previously diagnosed with diabetes mellitus.
- Acute Medical Status :Hospitalized patients.
- Physiological States: Pregnant females.Lactating females.
- Specific Comorbidities \& Conditions: Polycystic kidney disease.
- New York Heart Association (NYHA) class III or IV heart failure.
Show all 10Show fewer
- Known liver cirrhosis. or HIV/AIDS.
- Renal cancer.
- Active immunosuppression. or Recent chemotherapy or immunosuppressive therapy.
- History of organ transplantation.
Trial locations and contacts
2 sites in 1 country.
Egypt2 sites
Faculty of Medicine
Sohag, Egypt, 82525
Sohag University .Faculty of Medicine
Sohag
About this study
Official title: Screening of Prediabetes in End Stage Renal Disease on Dialysis
Prediabetes is a highly prevalent condition, affecting about one-third of adults in the United States Patients with prediabetes have an increased risk for diabetes, with 2% to 10% progressing to diabetes each yea Although prediabetes is frequently considered an intermediary stage in the progression between normoglycemia and diabetes, many individuals may have prediabetes for several years, while some may never progress.
- Medical subject headings
- Glucose Intolerance, Kidney Failure, Chronic
What is being measured
The primary outcome is the main question the study is designed to answer.
The prevalence of prediabetes in the End Stage Renal Disease (ESRD) on dialysis cohort.
Measured: "The time frame for measurement of the primary outcome (prevalence of prediabetes) with all diagnostic measurements (Fasting Plasma Glucose mg/dl) performed once per participant at the time of their inclusion in the study."
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jan 2026
- Study start13 Apr 2025
- Primary completion13 Sep 2025
- Study completion12 Oct 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ScreeningStudies of the same condition, open and under way.
- More trials run by Sohag UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 262 participants (actual)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hany Ahmed Mohamed, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07337083
- Sponsor's protocol ID
- Soh-Med-25-4--6PD
- Status last verified
- Apr 2025
- First submitted
- 4 Jan 2026
- Last updated
- 13 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 13 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Screening of Prediabetes in End Stage Renal Disease on Dialysis
- ClinicalTrials.gov ID
- NCT07337083
- Acronym / sponsor ID
- Soh-Med-25-4--6PD
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 262 participants (actual)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- 13 Apr 2025 (actual)
- Primary completion
- 13 Sep 2025 (actual)
- Study completion
- 12 Oct 2025 (actual)
- First posted
- 13 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Prediabetes is a highly prevalent condition, affecting about one-third of adults in the United States Patients with prediabetes have an increased risk for diabetes, with 2% to 10% progressing to diabetes each yea Although prediabetes is frequently considered an intermediary stage in the progression between normoglycemia and diabetes, many individuals may have prediabetes for several years, while some may never progress.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population is defined as adult patients (aged 18 years or older) with End-Stage Renal Disease (ESRD) who are currently on dialysis. This population will be recruited from a single center: Sohag Faculty of Medicine, Sohag University, Egypt.
Key inclusion criteria (1 listed)
- End stage renal disease on dialysis patients aged ≥ 18 years old.
Key exclusion criteria (10 listed)
- Patients previously diagnosed with prediabetes.
- Patients previously diagnosed with diabetes mellitus.
- Acute Medical Status :Hospitalized patients.
- Physiological States: Pregnant females.Lactating females.
- Specific Comorbidities \& Conditions: Polycystic kidney disease.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
The prevalence of prediabetes in the End Stage Renal Disease (ESRD) on dialysis cohort.
Time frame: "The time frame for measurement of the primary outcome (prevalence of prediabetes) with all diagnostic measurements (Fasting Plasma Glucose mg/dl) performed once per participant at the time of their inclusion in the study."
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jan 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Screening
Not yet recruiting
Improving Colorectal Cancer Screening Uptake Through Education and Stool-Based Testing Outreach
Colorectal Cancer (CRC) Screening, CRC Screening
Enrolling by invitationObservational study
Use of cfDNA in Monitoring and Guiding Treatment for Cervical Cancer
Cervical Cancer Screening
Recruiting
Improving Hepatocellular Carcinoma Screening
Magnetic Resonance Imaging, Hepatocellular Carcinoma
Not yet recruiting
Smartphone-enabled Hybrid Identification of Early CoLorectal Disease Using Blood-Based Cancer Testing Across TeXas
Colorectal Cancer (CRC) Screening
Not yet recruiting
C-Raven LDCT: Lung Cancer Screening Intervention
Lung Cancer Screening
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Screening and Pre Diabetic, run by Sohag University at 2 sites in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The prevalence of prediabetes in the End Stage Renal Disease (ESRD) on dialysis cohort. (time frame: "The time frame for measurement of the primary outcome (prevalence of prediabetes) with all diagnostic measurements (Fasting Plasma Glucose mg/dl) performed once per participant at the time of their inclusion in the study."). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jan 2026; AzTrials last refreshed its copy on 6 Nov 2026.